scholarly journals A retrospective cohort study to evaluate the relationship of airway hyperresponsiveness to type 2 biomarkers in persistent asthma

2021 ◽  
Vol 5 (1) ◽  
pp. 008-013
Author(s):  
Chan Rory ◽  
Kuo Chris RuiWen ◽  
Lipworth Brian
Keyword(s):  
Airway Hyperresponsiveness ◽  
Immunoglobulin E ◽  
Persistent Asthma ◽  
Specific Ige ◽  
Elevated Type ◽  
Challenge Testing ◽  
Specific Immunoglobulin E ◽  
Blood Eosinophils ◽  
Relationship Of

irway hyperresponsiveness (AHR) is a hallmark of persistent asthma measured using direct or indirect airway bronchial challenge testing. The purpose of this study is to investigate the putative relationships between type 2 inflammatory biomarkers, airway geometry (FEV1 and FEF25-75) and specific IgE (RAST or skin prick) to AHR. We performed a retrospective analysis of our database (n = 131) of patients with asthma. Of these subjects, 75 had a histamine challenge and 56 had a mannitol challenge. Fractional exhaled nitric oxide (FeNO) and specific immunoglobulin E (IgE) but not blood eosinophils were significantly higher in patients with AHR to either histamine or mannitol. FEV1 % and FEF25 - 75 % were significantly lower in patients with AHR. Elevated Type 2 biomarkers including FeNO and specific IgE but not blood eosinophils were associated with AHR. Highlights: FeNO and specific IgE but not blood eosinophils are raised in patients with airway hyperresponsiveness.

scholarly journals Enterotoxin-Specific Immunoglobulin E Responses in Humans after Infection or Vaccination with Diarrhea-Causing Enteropathogens

2000 ◽  
Vol 68 (10) ◽  
pp. 6077-6081 ◽  
Author(s):  
Firdausi Qadri ◽  
Muhammad Asaduzzaman ◽  
Christine Wennerås ◽  
Golam Mohi ◽  
M. John Albert ◽  
...  
Keyword(s):  
North American ◽  
Immunoglobulin E ◽  
Specific Ige ◽  
Cholera Vaccine ◽  
Total Ige ◽  
B Subunit ◽  
The North ◽  
Specific Immunoglobulin E ◽  
Oral Cholera Vaccine ◽  
Ige Response

ABSTRACT Cholera toxin (CT)-specific antibody responses of the immunoglobulin E (IgE) isotype in the sera of adult patients suffering from infection with either Vibrio cholerae O1, V. cholerae O139, or enterotoxigenic Escherichia coli(ETEC) were analyzed and compared with those in the sera of volunteers immunized with a bivalent B subunit O1/O139 whole-cell cholera vaccine. A significant IgE response to CT was observed in 90% of the patients with V. cholerae O1 infection (18 of 20; P = <0.001) and 95% of the patients with V. cholerae O139 infection (19 of 20; P = <0.001). Similarly, the majority of the patients with ETEC diarrhea (83%; 13 of 15) showed a positive IgE response to CT. Eight of 10 North American volunteers (80%) orally challenged with V. cholerae O1 showed CT-specific IgE responses (P = 0.004). In contrast, Swedish volunteers immunized with the oral cholera vaccine showed no IgE responses to CT (P value not significant). During the study period, total IgE levels in the sera of the diarrheal patients, the North American volunteers, and the Swedish cholera vaccinees alike remained unchanged. However, the total IgE levels in the sera of patients and healthy Bangladeshi controls were on average 89-fold higher than those in the sera of the healthy Swedish volunteers and 34-fold higher than those in the sera of the North American volunteers.

Proficiency Survey-Based Evaluation of Clinical Total and Allergen-Specific IgE Assay Performance

2010 ◽  
Vol 134 (7) ◽  
pp. 975-982 ◽  
Author(s):  
Robert G. Hamilton
Keyword(s):  
Allergic Disease ◽  
Immunoglobulin E ◽  
Diagnostic Algorithm ◽  
Specific Ige ◽  
Total Serum ◽  
Design Data ◽  
Ige Antibody ◽  
Marked Variability ◽  
Specific Immunoglobulin E ◽  
History Of

Abstract Context.—The diagnostic algorithm for human allergic disease involves confirmation of sensitization by detection of allergen-specific immunoglobulin E (IgE) antibody in individuals suspected of having allergic disease because of a history of allergic symptoms after known allergen exposure. Previous studies showed wide disparity among clinically reported allergen-specific IgE levels from different serologic assays. Objective.—To validate the relative analytic performance (sensitivity, interassay reproducibility, linearity/parallelism, intermethod agreement) of clinically used total and allergen-specific IgE assays by using College of American Pathologists' Diagnostic Allergy “SE” Proficiency Survey data. Design.—Data from 2 SE survey cycles were used to assess relative analytic performance of the ImmunoCAP (Phadia), Immulite (Siemens Healthcare-Diagnostics), and HYTEC 288 (HYCOR-Agilent Technologies) total and allergen-specific IgE assays. In each cycle, 2 recalcified plasma pools from atopic donors were diluted twice with IgE-negative serum and evaluated in approximately 200 federally certified clinical laboratories for total IgE and IgE antibody to 5 allergen specificities. Statistical analysis evaluated analytic sensitivity, linearity, reproducibility, and intermethod agreement. Results.—Interlaboratory intramethod, intermethod, and interdilution agreement of all 6 clinically used total serum IgE assays were excellent, with coefficients of variation (CVs) below 15%. Interlaboratory intramethod, and interdilution agreement of 3 clinically used allergen-specific IgE assays were also excellent with CVs below 15%. However, intermethod CVs identified between-assay disagreement greater than 20% in 80% of allergen-specific IgE measurements. Allergen reagents and patients' immune response heterogeneity are suggested probable causes. Conclusions.—Clinical total and allergen-specific IgE assays display excellent analytic sensitivity, precision, reproducibility, and linearity. Marked variability in quantitative estimates of allergen-specific IgE from clinically used automated immunoassays is a concern that may be ameliorated with component allergen use.

Relationship Of Toll-like Receptors 2 And 4 Gene Polymorphisms With Elevated Production Of Specific Immunoglobulin E

2012 ◽  
Vol 129 (2) ◽  
pp. AB82
Author(s):  
I.P. Kaidashev ◽  
O.V. Izmaylova ◽  
N.L. Kutsenko ◽  
O.A. Shlykova ◽  
L.E. Vesnina ◽  
...  
Keyword(s):  
Gene Polymorphisms ◽  
Immunoglobulin E ◽  
Toll Like Receptors ◽  
Specific Immunoglobulin E ◽  
Specific Immunoglobulin ◽  
Relationship Of

scholarly journals Prevalence of specific immunoglobulin E and G against Aspergillus fumigatus in patients with asthma

2019 ◽  
Author(s):  
Newsha Hedayati ◽  
Vida Mortezaee ◽  
Seyed Alireza Mahdaviani ◽  
Maryam Sadat Mirenayat ◽  
Maryam Hassanzad ◽  
...  
Keyword(s):  
Aspergillus Fumigatus ◽  
Severe Asthma ◽  
Immunoglobulin E ◽  
Clinical Symptoms ◽  
Specific Ige ◽  
Total Ige ◽  
Asthmatic Patients ◽  
Specific Immunoglobulin E ◽  
Specific Immunoglobulin ◽  
The Mean

Background and Purpose: Aspergillus fumigatus as a ubiquitous fungus can be found in the respiratory tract of the asthmatic and healthy people. The inhalation of Aspergillus spores leads to an immune response in individuals with asthma and results in the aggravation of the clinical symptoms. The present study aimed to investigate the prevalence of specific immunoglobulin E and G (IgE and IgG) against A.fumigatus in asthmatic patients.Materials and Methods: This study was conducted on 200 consecutive patients with moderate to severe asthma referring to Masih Daneshvari hospital Tehran, Iran, from January 2016 to February 2018. Skin prick test (SPT) was performed in all subjects with Aspergillus allergens. Moreover, all patients underwent specific IgE testing for Aspergillus using Hycor method. Enzyme immune assay was applied to measure total IgE and Aspergillus-specific IgG.Results: According to the results, the mean age of the patients was 45.8 years (age range: 18-78 years). The mean levels of total IgE and Aspergillus specific IgE in asthmatic patients were obtained as 316.3 (range: 6-1300 IU/ml) and 1.5 (range: 0.1-61.3 IU/ml), respectively. Out of 200 patients, 27 (13.5%), 65 (32.5%), 22 (11.0%), and 86 (43.0%) cases had positive Aspergillus SPT, total IgE of > 417 IU/ml, Aspergillus-specific IgE, and IgG, respectively. The level of these variables in patients with severe asthma were 16 (16.5%), 36 (37.1%), 15 (15.5%), and 46 (47.4%), respectively.Conclusion: As the findings indicated, reactivity to Aspergillus is a remarkable phenomenon in asthmatic patients. It is also emphasised that the climatic condition may affect the positive rate of hypersensitivity to Aspergillus.

scholarly journals Effect of exacerbation history on clinical response to dupilumab in moderate-severe uncontrolled asthma

2021 ◽  
pp. 2004498
Author(s):  
Jonathan Corren ◽  
Constance H. Katelaris ◽  
Mario Castro ◽  
Jorge F. Maspero ◽  
Linda B. Ford ◽  
...  
Keyword(s):  
Asthma Control ◽  
Forced Expiratory Volume ◽  
Severe Exacerbation ◽  
Uncontrolled Asthma ◽  
Phase 3 ◽  
Asthma Control Questionnaire ◽  
Elevated Type ◽  
Post Hoc ◽  
Blood Eosinophils

BackgroundThe phase 3 QUEST study (NCT02414854) in patients with uncontrolled, moderate-to-severe asthma has demonstrated the efficacy and safety of dupilumab 200 and 300 mg every 2 weeks versus placebo. This post hoc analysis assessed the effect of dupilumab on efficacy outcomes and asthma control across a range of historical exacerbation rates in patients with type 2−high asthma.MethodsAnnualised severe exacerbation rates over the 52-week treatment period, pre-bronchodilator forced expiratory volume in 1 s (FEV1) at weeks 12/52, and the 5-item Asthma Control Questionnaire (ACQ-5) score at 24/52 were assessed in patients with ≥1, ≥2, or ≥3 exacerbations in the previous year. Subgroups were stratified by baseline blood eosinophils ≥150 or ≥300 cells·μL−1 or baseline fractional exhaled nitric oxide ≥25 ppb and baseline inhaled corticosteroid dose.ResultsAcross all type 2−high subgroups, dupilumab versus placebo significantly reduced severe exacerbations by 54 to 90%, with greater improvements in patients with more exacerbations prior to study initiation. Similarly, improvements in FEV1 (least squares [LS] difference versus placebo: ≥1 exacerbation, 0.15 to 0.25 L; ≥2 exacerbations, 0.12 to 0.32 L; ≥3 exacerbations, 0.09 to 0.38 L; majority p<0.05) and ACQ-5 score (LS mean difference range: ≥1 exacerbation, −0.30 to −0.57; ≥2 exacerbations, −0.29 to −0.56; ≥3 exacerbations, −0.43 to −0.61; all p<0.05) were observed, irrespective of prior exacerbation history, across all subgroups.ConclusionsDupilumab significantly reduced severe exacerbations and improved FEV1 and asthma control in patients with elevated type 2 biomarkers irrespective of exacerbation history and baseline ICS dose.

scholarly journals Enriched-Baicalein Attenuates Allergy in Cells and Mice

2020 ◽  
Vol 2020 ◽  
pp. 1-8
Author(s):  
Mi-Young Yun ◽  
Ju-Im Jung ◽  
Sung-Min Park ◽  
Hwa-Jung Choi
Keyword(s):  
Immunoglobulin E ◽  
Inflammatory Cells ◽  
Specific Ige ◽  
Eosinophil Infiltration ◽  
Antiallergic Activity ◽  
Tryptase Level ◽  
Basophilic Leukemia

Enriched-baicalein (baicalein) from baicalin was prepared by fermentation of an SB extract with mycelium of Laetiporus sulphureus. To investigate the pharmacologic effects of baicalein, its antiallergic effect was measured in vitro and in vivo. Allergy was induced by intraperitoneal injection of ovalbumin (OVA) into Balb/c mice. As a result, baicalein showed antiallergic effects by inhibiting the release of β-hexosaminidase from immunoglobulin E- (IgE-) stimulated rat basophilic leukemia (RBL-2H3) mast cells without cytotoxicity after the methodology. After four weeks, the decrease of OVA-specific IgE level, decrease of histamine and tryptase level in serum, and then the decrease of the levels of T helper type 2 (Th2) cell-derived cytokines interleukin- (IL-) 4 and IL-13 in the splenocyte were observed. In a histological analysis for lung, baicalein excellently reduced eosinophil infiltration with the inhibition of characteristic lesions and inflammation including OVA-induced necrosis, numbers of inflammatory cells, and pulmonary edema. Therefore, these results showed that baicalein had excellent efficacy in the antiallergic activity.

scholarly journals VALIDA project: Validation of allergy in vitro diagnostics assays (Tools and recommendations for the assessment of in vitro tests in the diagnosis of allergy)

2020 ◽  
Vol 0 (0) ◽  
Author(s):  
María L. Casas ◽  
Ángel Esteban ◽  
Miguel González-Muñoz ◽  
Moisés Labrador-Horrillo ◽  
Mariona Pascal ◽  
...  
Keyword(s):  
Immunoglobulin E ◽  
Allergic Patient ◽  
Specific Ige ◽  
In Vitro Tests ◽  
Consensus Document ◽  
Specific Immunoglobulin E ◽  
The Impact

AbstractIn vitro allergen-specific immunoglobulin E (IgE) detection and quantification tests are routinely performed in clinical laboratories to diagnose patients with a suspected allergy. Numerous commercial assays are available to test for allergies, but the results can vary widely, thereby influencing both diagnosis and treatment. Given the challenges posed by differences in the various assays for in vitro determination of specific IgE, a group of experts has compiled in a document a series of recommendations on the implications that the use of a certain in vitro technique may have and the impact on the management of the allergic patient that the differences between the various techniques represent. The reading and analysis of this consensus document will help to understand the implications of the change of in vitro diagnostic method in the management of the patient with allergy, in the quality of life and in the socioeconomic costs associated with the disease.

Evaluation of a fully automated and completely quantitative allergen-specific IgE and total IgE detection assay

2021 ◽  
Author(s):  
Huimin Huang ◽  
Zhifeng Huang ◽  
Peiyan Zheng ◽  
Nili Wei ◽  
Xueqing Liang ◽  
...  
Keyword(s):  
Immunoglobulin E ◽  
Detection System ◽  
Specific Ige ◽  
Quantitative Detection ◽  
Total Ige ◽  
Detection Assay ◽  
Specific Immunoglobulin E ◽  
Specific Immunoglobulin

Based on the current urgent need for an in vitro quantitative detection system for allergens in most hospitals in China, we introduced a novel allergen-specific immunoglobulin E detection system that...

Blood Eosinophils, Specific Immunoglobulin E, and Bronchiolitis Severity

2021 ◽  
Author(s):  
Elie J. Mitri ◽  
David X. Zheng ◽  
Vebhav Garg ◽  
Cassandra C. Crifase ◽  
Nicole M. Herrera ◽  
...  
Keyword(s):  
Immunoglobulin E ◽  
Specific Immunoglobulin E ◽  
Specific Immunoglobulin ◽  
Blood Eosinophils
Sign in / Sign up

Export Citation Format

Share Document